This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Mascio, M.
Right arrow Articles by Perelson, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Mascio, M.
Right arrow Articles by Perelson, A. S.

 Previous Article  |  Next Article 

Journal of Virology, February 2003, p. 2271-2275, Vol. 77, No. 3
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.3.2271-2275.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

In a Subset of Subjects on Highly Active Antiretroviral Therapy, Human Immunodeficiency Virus Type 1 RNA in Plasma Decays from 50 to <5 Copies per Milliliter, with a Half-Life of 6 Months

Michele Di Mascio,1 Geethanjali Dornadula,2 Hui Zhang,2 Julie Sullivan,2 Yan Xu,2 Joseph Kulkosky,2 Roger J. Pomerantz,2 and Alan S. Perelson1*

Theoretical Division, Los Alamos National Laboratory, Los Alamos, New Mexico 87545,1 Dorrance H. Hamilton Laboratories, Center for Human Virology, Thomas Jefferson University, Philadelphia, Pennsylvania 191072

Received 7 March 2002/ Accepted 30 October 2002

Three of five virally suppressed human immunodeficiency virus type I (HIV-1)-infected patients treated with highly active antiretroviral therapy and followed intensively with a supersensitive reverse transcriptase PCR assay with a lower limit of quantitation of 5 copies/ml showed statistically significant viral load decays below 50 copies/ml, with half-lives of 5 to 8 months and a mean of 6 months. This range of half-lives is consistent with the estimated half-life of the latent HIV-1 reservoir in the peripheral blood. Those patients without decay of viral load in plasma may have significant cryptic HIV-1 residual replication.

* Corresponding author. Mailing address: MS-K710, T-10, Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM 87545. Phone: (505) 667-6829. Fax: (505) 665-3493. E-mail: asp{at}lanl.gov.

Journal of Virology, February 2003, p. 2271-2275, Vol. 77, No. 3
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.3.2271-2275.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., King, M. S. (2008). Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. USA 105: 3879-3884 [Abstract] [Full Text]  
  • Di Mascio, M., Markowitz, M., Louie, M., Hurley, A., Hogan, C., Simon, V., Follmann, D., Ho, D. D., Perelson, A. S. (2004). Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection. J. Virol. 78: 10566-10573 [Abstract] [Full Text]  
  • Weinberger, L. S., Schaffer, D. V., Arkin, A. P. (2003). Theoretical Design of a Gene Therapy To Prevent AIDS but Not Human Immunodeficiency Virus Type 1 Infection. J. Virol. 77: 10028-10036 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»